Charles Leath III

Dr. Charles Leath III

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2007 in Gynecologic Oncology
Verified
Journal Article
Closed access
CICharles Leath III
Charles Leath III
WHWarner K. Huh
Warner K. Huh
JHJohnny Hyde
Johnny Hyde
DCDavid E. Cohn
David E. Cohn
KRKimberly E. Resnick
Kimberly E. Resnick
MGMichael A. Gold
Michael A. Gold

1 February 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BKBeth Y. Karlan
Beth Y. Karlan
AOAmit Oza
Amit Oza
GRGary E. Richardson
Gary E. Richardson
DPDiane M. Provencher
Diane M. Provencher
VHVincent L. Hansen
Vincent L. Hansen
IVIgnace B. Vergote
Ignace B. Vergote
Purpose: To estimate the efficacy and toxicity of AMG 386, an investigational peptide-Fc fusion protein that neutralizes the interaction between the Tie2 receptor and angiopoietin-1/2, plus weekly paclitaxel in patients with recurrent ovarian cancer. Patients and Methods: Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer were randomly assigned 1:1:1 to receive paclitaxel (80 mg/m2 once weekly [QW], 3 weeks on/1 week off) plus intravenous AMG 386 10 mg/kg QW (arm A), AMG 386 3 mg/kg QW (arm B), or placebo QW (arm C). The primary end point was progression-free survival (PFS). Secondary end points included overall survival, objective response, CA-125 response, safety, and pharmacokinetics. Results: One hundred sixty-one patients were randomly assigned. Median PFS was 7.2 months (95% CI, 5.3 to 8.1 months) in arm A, 5.7 months (95% CI, 4.6 to 8.0 months) in arm B, and 4.6 months (95% CI, 1.9 to 6.7 months) in arm C. The hazard ratio for arms A and B combined versus arm C was 0.76 (95% CI, 0.52 to 1.12; P = .165). Further analyses suggested an exploratory dose-response effect for PFS across arms (Tarone's test, P = .037). Objective response rates for arms A, B, and C were 37%, 19%, and 27%, respectively. The incidence of grade ≥ 3 adverse events (AEs) in arms A, B, and C was 65%, 55%, and 64%, respectively. Frequent AEs included hypertension (8%, 6%, and 5% in arms A, B, and C, respectively), peripheral edema (71%, 51%, and 22% in arms A, B, and C, respectively), and hypokalemia (21%, 15%, and 5% in arms A, B, and C, respectively). AMG 386 exhibited linear pharmacokinetic properties at the tested doses. Conclusion: AMG 386 combined with weekly paclitaxel was tolerable, with a manageable and distinct toxicity profile. The data suggest evidence of antitumor activity and a dose-response effect, warranting further studies in ovarian cancer.

1 December 2003 in Gynecologic Oncology
Verified
Journal Article
Closed access
WHWarner K Huh
Warner K Huh
MPMatthew Powell
Matthew Powell
CICharles Leath III
Charles Leath III
JSJ.MIchael Straughn
J.MIchael Straughn
DCDavid E Cohn
David E Cohn
RARonald D Alvarez
Ronald D Alvarez

1 February 2002 in Gynecologic Oncology
Verified
Journal Article
Closed access
PDF file
JSJ.MIchael Straughn
J.MIchael Straughn
WHWarner K. Huh
Warner K. Huh
FKF.JOseph Kelly
F.JOseph Kelly
CICharles Leath III
Charles Leath III
MKMarc J. Kleinberg
Marc J. Kleinberg
RARonald D. Alvarez
Ronald D. Alvarez

14 January 2020 in Drugs
Verified
Journal Article
Closed access
PDF file
ACAlexander C. Cohen
Alexander C. Cohen
BRBrandon M. Roane
Brandon M. Roane
CICharles Leath III
Charles Leath III

6 July 2020 in Gynecologic Oncology
Verified
Journal Article
Closed access
WHWarner K. Huh
Warner K. Huh
WBWilliam E. Brady
William E. Brady
PFPaula M. Fracasso
Paula M. Fracasso
DDDon S. Dizon
Don S. Dizon
MPMatthew A. Powell
Matthew A. Powell
CACarol Aghajanian
Carol Aghajanian